After decades of failure, vaccines for RSV are on the way

2 November 2022

A landmark approval in infectious diseases could be achieved by the end of the year, after New York pharma giant Pfizer (NYSE: PFE) reported fast progress in its respiratory syncytial virus (RSV) vaccine program.

Citing strong efficacy at a pre-planned interim analysis, the company has stopped enrollment in the MATISSE trial of its unique bivalent RSV candidate RSVpreF, which is given to pregnant women to protect infants from birth.

Data monitors said the trial met the success criterion for one of two primary endpoints, with 81.8% efficacy against severe medically attended lower respiratory tract illness.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK